<DOC>
	<DOC>NCT00997945</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.</brief_summary>
	<brief_title>10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Provision of informed consent Histological and/or cytological confirmed advanced solid malignancies WHO performance status&lt;2 History of significant gastrointestinal impairment, as judged by the investigator, that could significantly affect the absorption of ZD4054 (Zibotentan) , including the ability to swallow the tablet whole. ALT or AST³2.5 ´ULRR. If liver metastases are present ALT or AST more than 5times ULRR, Serum bilirubin &gt; 1.5 x ULRR, Serum creatinine&gt;1.5 x ULRR or creatinine clearance of &lt;50mL/min calculated by CockroftGault Recent (&lt;14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed, Radical radiotherapy within the previous 4 weeks, or unresolved acute or subacute toxicities from prior radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Phase I, advanced solid malignancies, advance solid tumour</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>ZD4054 (Zibotentan)</keyword>
	<keyword>china</keyword>
	<keyword>PK</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>